JP2023542932A - 常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物 - Google Patents

常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物 Download PDF

Info

Publication number
JP2023542932A
JP2023542932A JP2023518198A JP2023518198A JP2023542932A JP 2023542932 A JP2023542932 A JP 2023542932A JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023542932 A JP2023542932 A JP 2023542932A
Authority
JP
Japan
Prior art keywords
cltx
cca
dose
blood
total daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542932A5 (https=
Inventor
ブルース サイモン
フォックス ジョナサン
サニ－ゴロッソ ラメイ
コメイリー アリ
スリダー アナンス
スコット ロバーツ メアリー
ティー．コリンズ マイケル
アイ．ガフニ レイチェル
ビー．エル．ロズコ ケリー
アール．ハートリー アイリス
エー．ポゾ カレン
Original Assignee
カルシリティクス セラピューティクス，インコーポレイティド
ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カルシリティクス セラピューティクス，インコーポレイティド, ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ filed Critical カルシリティクス セラピューティクス，インコーポレイティド
Publication of JP2023542932A publication Critical patent/JP2023542932A/ja
Publication of JP2023542932A5 publication Critical patent/JP2023542932A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2023518198A 2020-09-18 2021-09-16 常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物 Pending JP2023542932A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (2)

Publication Number Publication Date
JP2023542932A true JP2023542932A (ja) 2023-10-12
JP2023542932A5 JP2023542932A5 (https=) 2024-09-25

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518198A Pending JP2023542932A (ja) 2020-09-18 2021-09-16 常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物

Country Status (10)

Country Link
US (1) US20220087961A1 (https=)
EP (1) EP4213829A1 (https=)
JP (1) JP2023542932A (https=)
KR (1) KR20230112609A (https=)
AU (1) AU2021343475A1 (https=)
CA (1) CA3192684A1 (https=)
IL (1) IL301409A (https=)
MX (1) MX2023003129A (https=)
TW (1) TW202227046A (https=)
WO (1) WO2022060987A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230106582A (ko) 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형
EP4698162A1 (en) * 2023-04-21 2026-02-25 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094362A1 (ja) * 2003-04-23 2004-11-04 Japan Tobacco Inc. CaSRアンタゴニスト

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230106582A (ko) * 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094362A1 (ja) * 2003-04-23 2004-11-04 Japan Tobacco Inc. CaSRアンタゴニスト

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONG, BINGZI ET AL.: "Persistent Activation of Calcium-Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, a", JBMR PLUS, vol. 3, no. 7, JPN6025041087, July 2019 (2019-07-01), pages 1 - 9, ISSN: 0005703130 *
KIMURA SHUICHI ET AL.: "JTT-305, and orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hor", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. Vol.668, Nos.1-2, JPN6025041088, 2011, pages 331 - 336, ISSN: 0005703131 *

Also Published As

Publication number Publication date
KR20230112609A (ko) 2023-07-27
TW202227046A (zh) 2022-07-16
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
EP4213829A1 (en) 2023-07-26
AU2021343475A9 (en) 2024-05-02
US20220087961A1 (en) 2022-03-24
CA3192684A1 (en) 2022-03-24
MX2023003129A (es) 2023-08-04
AU2021343475A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US20220152058A1 (en) Methods and compositions for treating various disorders
US20220323445A1 (en) Reducing immunogenicity to pegloticase
US12465631B2 (en) Reducing immunogenicity to pegloticase
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US20220409620A1 (en) Reducing immunogenicity to pegloticase
US20200206247A1 (en) Oral b12 therapy
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
JP2023542932A (ja) 常染色体優性低カルシウム血症１型（ａｄｈ１）の治療のためのトリフェニルカルシリティック化合物
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
US20210085711A1 (en) Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
WO2026078027A1 (en) Dosage regimens for camlipixant in treating chronic cough
El Kossi 10b
Vandenbroucke et al. A case report of a rare cause of hypophosphatemic rickets--cystinosis
CN118829427A (zh) 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Hassan Utilization of Zoledronic Acid in the Treatment of Osteoporosis at a Major Inner-City Medical Center

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407